Meningococcal disease occurs worldwide with incidence rates varying from 1 to 1000 cases
per 100,000. The causative organism, Neisseria meningitidis, is an obligate commensal of …

Abstract Background The Meningococcal Antigen Typing System (MATS) was developed to
identify meningococcus group B strains with a high likelihood of being covered by the …

Meningococcal disease describes the spectrum of infections caused by Neisseria
meningiditis, including meningitdis, bacteremia, and bacteremic pneumonia. Two …

The control of meningitis, meningococcemia and other infections caused by Neisseria
meningitidis is a significant global health challenge. Substantial progress has occurred in …

Abstract Background In January 2005, a quadrivalent (serogroups A, C, Y, and W-135)
meningococcal conjugate vaccine was licensed for use in adolescents. This report …

This review article incorporates information from the 4th Global Meningococcal Initiative
summit meeting. Since the introduction of stringent COVID-19 infection control and lockdown …

Methods The ACIP Meningococcal Vaccines Work Group reviewed safety and
immunogenicity data from seven clinical trials of MenB-4C (2–7)(Novartis, unpublished data) …

The clinical spectrum of invasive meningococcal disease is diverse with meningitis and/or
septicaemia being the commonest modes of presentation. The severity of manifestations of …

The development of a comprehensive vaccine against meningococcal disease has been
challenging. Recent developments in molecular genetics have provided both explanations …

Background Invasive meningococcal disease (IMD) is a worldwide health issue that is
potentially preventable with vaccination. In view of its sporadic nature and the high diversity …